Benjamin O.Lang

Of Counsel

Tokyo + 81.3.6744.1605

Connect:

Share

Ben Lang has a wealth of experience advising Japanese and international clients on cross-border transactions. Having practiced for nearly 15 years in Tokyo and New York, Ben has advised on a wide variety of strategic and commercial transactions, including public and private M&A, divestitures, spin-outs, joint ventures, and other investments. He has a particular focus on the life sciences industry, where Ben also handles international co-development, licensing, distribution, and other arrangements and provides guidance to international clients on market entry and clinical trials in Japan. In addition, he has substantial experience working with financial institutions and energy industries in Japan.

Ben's recent transactions prior to joining Jones Day in 2017 include advising a large U.S. retailer in the divestment of its Japan operations, a U.S. renewable power company in the divesture of several Japan-based projects, a public Japanese company in the acquisition of a U.S. medical device manufacturer, and a U.S. telecommunications company in establishing a Japanese joint venture.

Ben has had a close association with Japan for more than 30 years, including an internship in a polymer research laboratory near Kyoto and working in a city hall in Hokkaido. He regularly works with clients in Japanese and English.

Experience

  • IMCD acquires Kuni ChemicalJones Day advised IMCD N.V. in the acquisition by subsidiary IMCD Japan of 100% of the shares of the speciality distribution company, Kuni Chemical Co., Ltd. from Japan Private Equity Co., Ltd.
  • Avient acquires DSM Protective Materials businessJones Day advised Avient Corporation (NYSE: AVNT), a leading provider of specialized and sustainable material solutions, in the $1.485 billion acquisition and financing of Koninklijke DSM N.V.’s protective materials business, a leading specialty engineered materials business built around the invention of Dyneema®, the world’s strongest fiber.
  • Sanofi announces carve-out creating EUROAPI and spin-off of approximately 58% of shares to its shareholdersJones Day advised Sanofi in the carve out creating EUROAPI (a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients) and the listing of this entity on Euronext Paris and the placement of 12% to the French State (through French Tech Souveraineté) for a price of up to €150 million.
  • Otsuka acquires new, high-sensitivity biomarker measurement technology from Konica MinoltaJones Day advised Otsuka Pharmaceutical Co., Ltd. in the acquisition of Konica Minolta's new high-sensitivity biomarker measurement technology that uses SPFS (surface plasmon field-enhanced fluorescence spectroscopy) technology.
  • Cardinal Health sells its Cordis business to Hellman & Friedman for approximately $1 billionJones Day advised Cardinal Health in connection with the divestiture of its Cordis business to Hellman & Friedman for approximately $1 billion.
  • EagleTree Capital acquires IntegreonJones Day advised EagleTree Capital in connection with the acquisition and financing of Integreon, a leading global managed services provider, from NewQuest Capital Partners.
  • ETS acquires TOEFL® assets of Council on International Educational Exchange (CIEE)-JapanJones Day advised ETS in the acquisition of the TOEFL® assets of the Council on International Educational Exchange (CIEE)-Japan.
  • STERIS acquires Cantel Medical for $3.6 billionJones Day advised STERIS plc in its acquisition of Cantel Medical Corp, a global provider of infection prevention products and services primarily to endoscopy and dental customers, for $3.6 billion.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Furukawa Electric and Superior Essex global joint venture finalizedJones Day advised Furukawa Electric Co., Ltd. in its finalization of a global joint venture with Superior Essex Inc.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Torii Pharmaceutical acquires exclusive marketing and licensing rights from BioCryst for BCX7353 in JapanJones Day represented Torii Pharmaceutical Co., Ltd. in drafting, reviewing, and negotiating its commercialization and license agreement with BioCryst Pharmaceuticals, Inc.
  • Kaga Electronics acquires Fujitsu Electronics Inc.Jones Day advised Kaga Electronics Co., Ltd. in its acquisition of Fujitsu Electronics Inc.
  • Hudson's Bay Company sells Gilt Groupe K.K. to Gladd Inc.Jones Day advised Hudson's Bay Company in the sale of its subsidiary, Gilt Groupe K.K., to Gladd Inc.
  • MassMutual International sells 85.1 percent of MassMutual Japan to Nippon LifeJones Day advised MassMutual International LLC in its sale of 85.1 percent of the shares of MassMutual Japan, MassMutual's wholly-owned life insurance and wealth affiliate, to Nippon Life for JPY104.2 billion (approximately US$955 million).
  • PAG invests in Key Safety Systems to finance acquisition of global assets of Takata CorporationJones Day represented PAG Asia Capital Ltd. and PAG Asia II LP in connection with its investment in Key Safety Systems, a subsidiary of China-based Ningbo Joyson Electronic Corporation, to finance the acquisition of substantially all of the global assets of Takata Corporation out of bankruptcy in the U.S. and Japan and certain non-bankruptcy transactions elsewhere in the world.
  • PAG Holdings sells minority interest to Blackstone Strategic Capital Holdings FundJones Day represented PAG Holdings Ltd., one of Asia’s largest independent alternative asset managers, in connection with its sale of a minority interest in PAG to the Blackstone Strategic Capital Holdings Fund.
    • View All

    July 2022 Newsletters

    Vital Signs: Digital Health Law Update | July 2022

    March 2022 Newsletters

    Vital Signs: Digital Health Law Update | Winter 2022

    August 2021 Newsletters

    Vital Signs: Digital Health Law Update | Summer 2021

    May 2021 Alert

    Additional Changes in German Foreign Direct Investment Control

    April 2021 Newsletters

    Vital Signs: Digital Health Law Update | Spring 2021

    January 2021 Newsletters

    Vital Signs: Digital Health Law Update | Winter 2021

    November 2020 Newsletters

    Japan Legal Update Vol. 53 | Autumn 2020

    October 2020 Newsletters

    Vital Signs: Digital Health Law Update | Fall 2020

    August 2020 Newsletters

    Japan Legal Update Vol. 52 I Summer 2020

    July 2020 Newsletters

    Vital Signs: Digital Health Law Update | Summer 2020
    View All

    Speaking Engagements

    • November 2021
      医薬品企業法務研究会：英文契約におけるボイラープレート条項
    • October 2020
      医薬品企業法務研究会：英文供給契約／コモンローの視点から見た不可抗力条項

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.